ArticleBMC infectious diseases2025
Assessing HIV/AIDS patients' access to antiretroviral drugs using the healthcare accessibility framework: a cross-sectional study from Shandong, China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAntiretroviral drugs are important for HIV/AIDS patients, but we know little about the real-life barriers patients face in accessing them. Following the Levesque framework, this study described the five abilities of HIV/AIDS patients in Shandong Province to perceive, to seek, to reach, to pay and to engage in accessing antiretroviral drugs and the factors associated with them.
methodsA cross-sectional questionnaire survey, using convenience sampling, was conducted among HIV/AIDS patients in three AIDS-designated hospitals in Shandong Province. We used catastrophic cost methods and the HIV Treatment Adherence Self-efficacy Scale to assess patients' ability to pay and engage, respectively.
resultsA total of 301 participants completed the questionnaire, with 20.9% having a CD4 cell count of less than 200 cells/µL. For the ability to perceive, only 16.6% of respondents self-reported low knowledge of HIV progression and medication. For the ability to seek, 24.3% self-reported having experienced social discrimination, and 21.9% reported 'choosing not to seek health insurance reimbursement due to fear of privacy disclosure. For the ability to reach, the average time spent on purchasing drugs was 2.1 ± 1.3 h, with respondents living in rural areas and having low levels of education most likely to spend more hours. For the ability to pay, the overall incidence of catastrophic health expenditures for drugs was 28.9%. For the ability to engage, the overall median score on the HIV-ASES scale was 118.0 (IQR: 107-120), and 69.4% had high treatment compliance. Respondents who experienced drug toxicities were more likely to have poorer treatment compliance (OR = 2.12, P = 0.011).
conclusionsIn general, access to antiretroviral drugs for HIV/AIDS patients was relatively good, while their ability to reach and pay was unsatisfactory. There should be a great concern for health education intervention and geographical accessibility of antiretroviral drugs in healthcare institutions. Policy should focus on the impact of social discrimination and drug toxicity on access to antiretroviral drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.